

---

# Multidrug Resistant *Escherichia coli* Isolated from Asymptomatic School Going Children in Kibera Slum, Kenya

N. J. Gitahi<sup>1\*</sup>, P. B. Gathura<sup>1</sup>, M. M. Gicheru<sup>2</sup>, T. W. Githinji<sup>3</sup> and A. Nordin<sup>4</sup>

DOI: 10.9734/bpi/tamb/v2

---

## ABSTRACT

Pathogenic *Escherichia coli* are of different types, currently grouped into six groups depending on the virulence gene(s) they possess. This study isolated pathogenic *E. coli* from 580 stool samples obtained in the month of August, 2016. The samples were obtained from asymptomatic school going children in one of the biggest urban slums in Kenya. Ten primary schools were randomly sampled and 40 to 80 stool samples collected from each school depending on the school population. Both gender and age were considered when sampling. Data obtained was analysed using single factor ANOVA to test association between school location and levels of infection with pathogenic bacteria. A total of 244 (17%) samples had *E. coli*. Out of these, 38 (6.5%) were shown to have one or a combination of the pathogenic genes, namely: *ipaH*, *virF*, *st2*, *daaE*, *eae*, *aafII*, *stx1*, *bfp*, *lt* and *stII* and were thus classified into seven groups. Of the pathogenic isolates 35 (21.2%) were multidrug resistant. There was an association between school location and the prevalence of pathogenic bacteria. In conclusion, asymptomatic school going children in the slum were found to be infected with multidrug resistant pathogenic *E. coli*.

**Keywords:** Enteropathogenic; *E. coli*; multidrug resistance; school going children; asymptomatic.

## 1. INTRODUCTION

*Escherichia coli* form the normal flora of human and other mammals as the gut microbiota [1,2]. *E. coli* colonizes the gastrointestinal tract of infants within hours of birth, establishing mutual benefits with the host [1]. On colonization, *E. coli* will remain harmless to the host, only causing infection when the mutual environment is disturbed and in immune suppressed hosts. Pathogenic *E. coli* are of different types depending on the virulence gene(s) they possess [1].

Differentiating pathogenic strains has largely depended on serotyping methods [2].

Though serotypes are useful in pathogenic *E. coli* identification, they cannot be used to characterize the clinical syndromes of the strains. It is also a time consuming and expensive method, requiring well trained manpower. Identification of the specific virulence factors(s) in the pathogenic bacterial has been achieved through genotypic methods that detect specific genes encoding the pathogenic characteristics of the *E. coli* [1]. Based on the presence of virulence genes and ability to cause disease pathogenic *E. coli*, were classified as following pathotypes: Enteropathogenic *E. coli* (EPEC), enterotoxigenic *E. coli* (ETEC), enteroinvasive *E. coli* (EIEC), enteroaggregative *E. coli* (EAEC) shiga toxin– producing *E. coli* (STEC) and diffusely adherent *E. coli* (DAEC). Hybrid pathotypes have also been described including the enteroaggregative hemorrhagic *E. coli* (EAHEC) carrying both the STEC

---

<sup>1</sup>Department of Public Health Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Nairobi, Kenya.

<sup>2</sup>Department of Zoological Sciences, School of Pure and Applied Sciences, Kenyatta University, Nairobi, Kenya.

<sup>3</sup>School of Biological and Physical Sciences, University of Nairobi, Kenya.

<sup>4</sup>Department of Energy and Technology, Faculty of Natural Resources and Agricultural Sciences, Swedish University of Agricultural Sciences, Sweden.

\*Corresponding author: E-mail: nduhiugitahi@gmail.com;

and EAEC associated genes [2], such hybrid was reported by Franz et al. [3] as EAHEC serotype O104:H4.

*E. coli* are one of the bacterial pathogens of international concern regarding antibacterial resistance according to WHO [4]. *E. coli* can develop resistance through different ways but mostly through mutation, resulting in fluoroquinolone resistance. The bacteria can also acquire mobile genetic elements including; plasmids, transposons, integrons and gene cassettes resulting in resistance to penicillins (ampicillin or amoxicillin) as well as to third generation cephalosporins [4]. Resistance to cephalosporins has been shown to be caused by extended spectrum beta-lactamases (ESBLs), enzymes which destroy beta-lactam antibiotics. *E. coli* has the ability to acquire ESBLs, causing them to be resistance to Beta-lactams [5]. The presence of diarrheagenic *E. coli* in asymptomatic individuals has been reported in several studies and it is attributed to a number of observations including, development of protective antibodies early in life against diarrheagenic *E. coli*, as well as host susceptibility. This has been shown in children growing up in endemic areas [6]. Though the actual process leading to diarrheal is not clearly understood [7], non-specific host barriers, such as internal microbiota, intact mucus layer and epithelial cell layers have been postulated to prevent diarrheal episodes [8]. Bacterial factors inclining some pathogens to diarrhoea has also been shown in EPEC as a factor [9]. Research clearance was from National Commission for Science, Technology and Innovation (NACOSTI) and Ethical clearance through the Kenyatta University Ethical Review Committees. The objective of this study was to determine the prevalence of pathogenic *E. coli* infection in asymptomatic school going children and establish their antibiotic resistance patterns using phenotypic and genotypic methods.

## **2. MATERIALS AND METHODS**

### **2.1 Study Area**

The study was carried out in primary schools located in Kibera informal settlement, Nairobi County, Kenya. Kibera is located at an altitude of 1670 m above sea level, at longitude 1°17' East and latitude 36°, 50' South and it is about 140 Km South of Equator. Due to poor infrastructure and drainage the slum is heavily polluted by human and animal excreta, organic and inorganic waste littering the open sewage lines. The area can be characterised by lack of sufficient sanitation and poor water supply which results in frequent waterborne disease outbreaks [10].

### **2.2 Escherichia coli Culture**

Five grams of faecal sample was weighed and suspended in 45 ml of buffered peptone water to make a 1:9 ( $10^{-1}$ ) dilution. Further, a 10-fold serial dilutions were made;  $10^{-2}$ ,  $10^{-3}$ ,  $10^{-4}$  in sterile physiological saline solution (0.85%). Chromocult coliform agar (Merck Millipore Corporation, Germany) was prepared according to the manufacturer's instructions and kept at 50°C in water bath prior to use. One millilitre of the diluted and vortexed samples ( $10^{-3}$ ,  $10^{-4}$ ) was transferred into well labelled sterile petri dishes and 15 ml of the cooled medium was added. The plates were thoroughly mixed avoiding spillage. The media was allowed to solidify at room temperature before being incubated at 44.5°C, 18 h. Characteristic colonies were examined, counted and recorded as total thermo-tolerant coliforms (appearing as salmon red) or total *E. coli* (appearing as dark-blue to violet colonies). *E. coli* were confirmed by overlaying the dark-blue to violet colonies with Kovacs reagent and observing for a cherry-red colour change. Four characteristic colonies of *E. coli* per stool sample were sub-cultured on to clean Chromocult agar to obtain distinct colonies. Colonies embedded in the media were sub-cultured by piercing the pour plate agar using a sterile straight wire. The pure cultures as well as a pool of all the four different isolates from a single sample were stored in skimmed milk at -80°C for further characterization.

### **2.3 DNA Preparation from Bacteria Colonies and Multiplex Polymerase Chain Reaction (PCR)**

Only pure bacterial cultures were used for DNA preparation. Three distinct colonies were picked from agar plates containing pure culture with a sterile wire loop and suspended in 0.5 ml sterile distilled

water. The suspension was then placed in a water bath and heated to boil for 30 min. After cooling to room temperature the suspension was centrifuged at 2000 g and the supernatant was decanted and stored at -20°C as DNA templates.

Due to the large number of *E. coli* isolates, first the pools were sub-cultured, DNA isolated and tested for the presence of pathogenic *E. coli* using multiplex PCR. For pools that were positive, individual isolates making that specific pool were individually analysed. The PCR was carried out using a Veriti 96 wells thermocycler (Applied Biosystems, model 9902, Singapore) in 0.2 ml PCR tubes. A 25 µl reaction mix was prepared by mixing 12.5 µl of PCR master-mix (Taq polymerase 0.05 U/µl, 0.4 mM of each dNTP, 4mM MgCl<sub>2</sub>) (Biolabs Inc., New England) with ten pairs of specific primers (10 pmol) at 0.5 µl each [11] and 2.5 µl DNA template. Primers used for amplification of products encoding for pathogenic genes in *E. coli* are shown in Table 1.

*E. coli* were amplified with a program of initial heating at 94°C for 5 min followed by 94°C, 1.5 min minutes denaturation, 1.5 min at 60°C primer annealing and at 72°C for 1.5 min elongation for 35 cycles, with a final extension of 72°C for 7 min. The PCR products were kept at -20°C until gel electrophoresis was done. The PCR products were visualized following electrophoresis in a 1.5% agarose (Genetics analysis grade, Fisher Scientific, New Jersey) gel stained with 0.02% ethidium bromide and amplicons identified against molecular marker (50 bp DNA ladder, England Biolab) run long side the samples. A UV transilluminator digital camera (Gelmax 125 imager, Cambridge UK) with a UVP software interphase computer (Upland CA, USA) was used to visualize DNA bands relative to the molecular weight maker. For confirmation the positively identified PCR products were submitted for sequencing (ABI 3500XL Genetic Analyzer).

**Table 1. Primers used for patho-typing *E. coli* isolates**

<b>Primer sequence 5'-3'</b>	<b>PCR product size (pb)</b>	<b>Encoded gene</b>	<b>References</b>
F-CTC GGC ACG TTT TAA TAG TCT GG R-GTG GAG AGC TGA AGT TTC TCT GC	933	<i>ipaH</i>	[11]
F-AGC TCA GGC AAT GAA ACT TTG AC R-TGG GCT TGA TAT TCC GAT AAG TC	618	<i>virF</i>	[11]
F-ATC CTA TTC CCG GGA GTT TAC G R-GCG TCA TCG TAT ACA CAG GAG C	584	<i>stx2</i>	[12]
F-GAA CGT TGG TTA ATG TGG GGT AA R-TAT TCA CCG GTC GGT TAT CAG T	542	<i>daaE</i>	[11]
F-TCA ATG CAG TTC CGT TAT CAG TT R-GTA AAG TCC GTT ACC CCA ACC TG	482	<i>eae</i>	[13]
F-CAC AGG CAA CTG AAA TAA GTC TGG R-ATT CCC ATG ATG TCA AGC ACT TC	378	<i>aafII</i>	[11]
F- CAG TTA ATG TGG TGG CGA AGG R- CAC GCA ACA ATG TAA CCG CTG	348	<i>stx1</i>	[12]
F-GGA AGT CAA ATT CAT GGG GGT AT R- GGA ATC AGA CGC AGA CTG GTA GT	300	<i>bfp</i>	[13]
R-TCC TTC ATC CTT TCA ATG GCT TT F-GCA CAC GGA GCT CCT CAG TC	218	<i>lt</i>	[13]
R-AAA GGA GAG CTT CGT CAC ATT TT F-AAT GTC CGT GCG TTA GGA C	129	<i>stII</i>	[13]

#### **2.4 Antimicrobial Sensitivity Test (AST) for Confirmed *E. coli* Isolates**

Bacteria inoculum for the antimicrobial resistance test was prepared by touching the top of at least 2 to 3 well isolated colonies with a sterile wire loop and then transferred into sterile normal saline solution (0.85% NaCl). The inoculum was emulsified on the inside of the tube to avoid clumping of the cells and turbidity adjusted to a 0.5 McFarland. A standard bacterium, *E. coli* ATCC 25922 was included in every test as antibiotic sensitivity breakpoint control. Six antimicrobial discs were placed on a single Muller Hinton agar plate with a sterile multidisc dispenser. One hundred and sixty five (165) *E. coli* isolates were tested against twelve antimicrobial agents namely; Tetracycline (30 mg,

TE); Ciprofloxacin (5 mg, CIP); 30 mg Naladixic acid (NA); 25 mg Trimethoprim-Sulfamethaxone (SXT); 30mg Ceftriaxone (CRO); 10 mg Amoxycillin-clucianic acid (AMC); 30 mg Ceflazime (CAS); 10 mg Ampicillin (AMP); 30 mg Chloramphenicol (C); 10 mg Gentamycin (CN); 10 mg Streptomycin (S), CXM; 30 mg Cefuroxicin (CXM) according to the CLSI [14] guidelines. The 12 antimicrobial agents are classified into 9 subclasses by CLSI [14].

## 2.5 Genotypic Characterization of Bacteria Isolates for Antimicrobial Resistance

Seventy five of the 165 *E. coli* isolates tested for antimicrobial sensitivity by the disc diffusion test were selected for genotypic characterization based on their phenotypic profiles. The isolates were tested for the presence of genes encoding for resistance to tetracyclines, quinolones and sulfonamides. Presence of four tetracycline resistance genes; *tet A*, *tet B*, *tet C* and *tet O* and two sulfonamides resistance genes namely *sul1* and *sul2* was tested. Multiplex PCR was carried out and primers used for amplification of products encoding for the resistant genes to the three antibiotic classes (Table 2).

## 3. RESULTS

A total of 221 stool samples had *E. coli* isolated, out of which 38 (6.5%) were pathogenic *E. coli*. These were distributed at different frequencies in the 11 schools studied with 4 (36%) schools having none isolated (Table 3). Using multiplex PCR, 83/555 (15%) pooled *E. coli* positive samples were shown to have one or a combination of the virulence genes and were thus classified into seven groups. Seventeen (3.1%) of the pools had the *eae* gene and were classified as atypical enteropathogenic. Thirty two (5.8%) pooled isolates were enterohemorrhagic forming the highest number followed by enterotoxigenic at (13/555) 2.3%, diffusely adherent at (12/555) 2.16%, enteroaggregative at (4/555) 0.72%, typical enteropathogenic at (3/555) 0.54% and lastly enteroinvasive at (2/555) 0.36%. A hundred and twenty three (20%) single *E. coli* isolates from 113 faecal samples were subjected to PCR and characterized into 6 pathotypes, with EHEC having 33 (27%) isolates, EPEC (typical and atypical) with 30 (24%) isolates, DAEC at 28 (23%) isolates, ETEC at 26 (21%) isolates, EAggEC with 5 isolates and lastly EIEC had only one isolate (Table 4).

**Table 2. Primers used for identifying tetracyclines and sulphonamides encoding genes in selected bacteria isolates**

Primer sequence 5'-3'	PCR product (pb)	Encoded gene	References
F-GTGAAACCCAACATACCCC R-GAAGGCAAGCAGGATGTAG	577	<i>Tet A</i>	[15]
F-CCTCAGCTTCTCAACGCGTG R-GCACCTTGCTGAGACTCTT	635	<i>Tet B</i>	[15]
F-ACTTGGAGCCACTATCGAC R-CTACAATCCATGCCAACCC	880	<i>Tet C</i>	[16]
R-AACTTAGGCATTCTGGCTCAC R-TCCCACTGTTCCATATCGTCA	515	<i>Tet O</i>	[17]
F-TTCGGCATTCTGAATCTCAC R-ATGATCTAACCCCTCGGTCTC	822	<i>Sul1</i>	[16]
F-TTCGGCATTCTGAATCTCAC R-ATGATCTAACCCCTCGGTCTC	285	<i>Sul2</i>	[16]

Multiple infections with more than one pathogenic *E. coli* were observed in 10 (8.8%) individuals. Three (2.0%) children had EHEC and EAggEC combined infection, another 4 (3.5%) children had EPEC and EIEC. A combined infection of EHEC, EAggEC and DAEC was observed in one (0.9%) child. Also observed in single individual child were EHEC together with EIEC and EPEC with EAgg EC (Table 4).


### 3.1 Multidrug Resistant Profiles of *E. coli* Isolates

One (0.6%) *E. coli* isolate was resistant to the eight antibiotics tested, 3 (1.8%) were resistant to seven drugs, 6 (3.6%) were resistant to six drugs, 18 (10.9%) were resistant to 5 drugs while 33 (20%) were resistant to 4 drugs. Thirty five (21.2%) were shown to be resistant to 3 drugs (Fig. 1).

**Table 3. Prevalence of pathogenic *E. coli* per school in the study area**

Schools	No sample per school	<i>E. coli</i> (Isolated) per school	Pathogenic <i>E. coli</i> n (%)
A	59	42	6 (14.2)
B	38	2	2 (0)
C	62	37	3 (5.4)
D	44	0	0 (0)
E	79	42	10 (23.8)
F	19	15	3 (20)
G	80	49	14 (28.6)
H	53	1	1 (0)
I	30	0	0 (0)
J	69	30	1 (0.33)
K	47	3	1 (33.3)
Totals	580	221	38
% Prevalence in the study area			6.5%

Phenotypically the antimicrobial subclass with the highest number of resistant isolates was sulfonamides with 115 (70%) isolates, this was followed by aminopenicillin with 97 (59%) isolates, tetracyclines had 91 (55%), aminoglycoside with 74 (45%) isolates, fluoroquinolones at 37 (22%) and phenicols had 24 (15%) resistant isolates. The other three subclasses had less than 10 (6%) resistant isolates (Fig. 2).



**Fig. 1. Percentage of multidrug resistant *E. coli***

Genes encoding for resistance to three antimicrobial subclasses were tested in 74 out of 165 phenotypically resistant isolates. One (1.4%) isolate had *TetA* gene, 6(8.1%) had *TetB* gene, 14 (19%) had *TetC* gene and none had *TetO* gene. Sulfonamides gene (*Sul1*) was only found in 10 (14%) isolates while none of the isolates had the *Sul2* gene.

### 3.2 Molecular Sequencing of Selected *E. coli* Isolates

The *eae* gene encoding the outer membrane protein was demonstrated in 5 *E. coli* isolates submitted for gene sequencing. The *eae* gene in the 5 isolates had blastn alignment identity of 99%, 98 and 94% with standard *E. coli* O157:H7, EP 057 isolate and *E.coli* O157:H7, respectively. These similarities confirmed the identity of the PCR products obtained from *E. coli* isolated from the asymptomatic school going pupils. Heat labile enterotoxin (*Lt*) genes were demonstrated as *eltB* and


eltA flanked by IS600 and IS1294. Two isolates processing the heat labile enterotoxin B encoding genes were submitted for sequencing. The sequences alignment with blastn gave a 99 and 84% identity for isolates 103a and 582a, respectively. Heat stable enterotoxin (*StII* gene) was shown in two isolates which were submitted for sequencing. The PCR products for the *StII* gene were sequenced and the sequences aligned using blastn giving 74 and 100% alignment respectively. One isolate with the *bfpA* gene encoding for major structure subunit of bundle forming pilus, had gene alignment identity at 99%.

**Table 4. Molecular characterization of pooled positive *E. coli* from stool (N=555)**

PCR genotype	Prevalence (n)	Genes demonstrated
Enterohemorrhagic <i>E. coli</i> (EHEC)	5.76%, (32/555)	<i>stx1, stx2, eae</i>
Atypical Enteropathogenic <i>E. coli</i> (EPEC)	3.06%, (17/555)	<i>eae</i>
Typical Enteropathogenic <i>E. coli</i> (EPEC)	0.54%, (3/555)	<i>eae, bfp</i>
Enterotoxigenic <i>E. coli</i> (ETEC)	2.34%, (13/555)	<i>lt, stII</i>
Diffuse adherent <i>E. coli</i> (DAEC)	2.16%, (12/555)	<i>daaE</i>
Enteroaggregative <i>E. coli</i> (EAaggEC)	0.72%, (4/555)	<i>aafII</i>
Enteroinvasive <i>E. coli</i> (EIEC)	0.36%, (2/555)	<i>lpaH, VirF</i>

#### 4. DISCUSSION

Pathogenic *E. coli* were characterized using multiplex PCR to demonstrate the presence of characteristic virulence genes. A prevalence of 17% obtained in this study was much lower compared to Rono et al. [18], who reported a prevalence of 34.2% in diarrheal samples. The difference in the observations being attributed to the fact that while this study sampled asymptomatic pupils, Rono et al. [18] worked with diarrheal patients.



**Fig. 2. Drug resistant patterns of pathogenic *E. coli* isolates from stool samples, N=165**

Molecular analysis of pathogenic *E. coli* isolates revealed that 13 (2.3%) samples had the enterotoxigenic (ETEC) genes, *LT* or the *ST 2*. Vidal et al. [11] described ETEC having one or more enterotoxins; heat labile (LT) *LT1* and *LT2* or the heat stable (ST) as *STa* and *STb*. In the present study, three children had typical EPEC with both the *eae* and *bfp* genes. Another 17 pupils had atypical EPEC having only the *eae* gene. These findings compares well with those reported by Bugarel et al. [19] and Vidal et al. [11] who observed a ratio of 1:3 and 1:4, typical to atypical EPEC

respectively. EPEC has proteins involved in attaching and effacement of the host cells microvilli. It has the EPEC adherence factor (EAF) plasmid and gene cluster encoding the bundle-forming pili (*bfp*) gene. Typical EPEC are those isolates with the EAF plasmid, those with the *bfp* gene but lack the EAF plasmid are classified as atypical EPEC. EIEC had the least number of isolates with only 2 (0.36%) children positive. This compares with other findings where none out of 509 stool samples yielded EIEC [11]. Rono et al. [18] made comparable observations, with EIEC isolation being the second last frequently isolated, at 3 out of 100 samples. EIEC possess a gene located in a virulence plasmid (Plnv) 140 MDa encoding type III secretion system. Highest number of isolates were found to be EHEC, with 32 out of 555 children positive. The isolates had a combination of *eae* gene with either *stx1* or *stx2* genes. Several authors have reported different distributions in the prevalence of different pathogenic *E. coli*. Some have reported EAEC as the most frequent; others had EAaggEC being the most frequent, while ETEC was shown by a different study as the most frequent. EPEC has also been identified by a different study as the most prevalent in Kenya [20,21,22,23].

Unlike Vidal et al. [11] who observed one patient out of 509 with mixed enteropathogenic *E. coli*, this study had 10 individuals out of 555 with mixed enteropathogenic infections. While 9 of the 10 had combinations of two different enteropathogenic *E. coli*, one of the children had three pathogenic *E. coli* characterized (EHEC, EAaggEC and DAEC). These findings are an indication that clinical symptoms alone, may not be conclusive in the diagnosis of enteropathogenic *E. coli* infections. Resistance to sulfonamides was the highest at 70%, this was followed by ampicillin at 59%, tetracycline 55%, streptomycin 41%, nalidixic acid at 16% and chloramphenicol at 15%. The findings in this study agree with Christabel et al. [24] who reported high resistance of environmental isolates from Kibera slums. Though the frequencies were not in agreement with this study, the general profile of resistance is comparable. In this study prevalence of resistance to cephalosporins (ceftriaxone, cefuroxime and ceftazidime) were very low at 4, 0.7 and 2%, respectively, resistance by *E. coli* to cephalosporins is mainly by the extended spectrum beta-lactamases (ESBLs) enzymes. These enzymes are able to destroy most of the beta-lactam antibiotics [4]. ESBLs can be transferred between bacteria species. In a report on resistance to antibacterial drugs in selected bacteria of international concern WHO, [4] the report gave a range of resistance *E. coli* to third generation cephalosporin in thirteen African Countries at 2-70%. This was within the levels of this study which had 4% resistant to ceftriaxone.

Only 31 (18.7%) pathogenic isolates were sensitive to all the 12 antibiotics tested, 21(12.7%) were resistant to only one of the 12 antibiotics, while the other 113 (68.5%) were resistant to more than 2 antibiotics. Isolates resistant to 3 or more antibiotics were 35(21.2%) thus classified as multidrug resistant (MDR) isolates. Those resistant to any four of the 12 antibiotics were 33(20%), those resistant to 5 antibiotics were 18(10.9%), resistant to 6 antibiotics were 6(3.6%) and those resistant to 7 antibiotics were 3(1.8%) isolates. Multidrug resistant *E. coli* has been reported on environmental isolates at 40% from the same study area. These findings have slightly lower frequency compared to those reported in this study, which could be attributed to the differences between human isolates and environmental isolates. The findings however agrees with Kipkorir et al. [25] who reported 42.2% MDR *E. coli* isolates from faecal specimens obtained from patients ages 2 weeks to 82 years. The patients had gastroenteritis and the study was in Kitale, Kenya. Oundo et al. [26] also reported 65.5% MDR *E. coli* isolates from asymptomatic food handlers in Kenya, which was very close to this study's 68.5%. They however reported resistance to cefuroxime at 6.9% which was much higher than 0.7% in the current study, which could be attributed to difference in the age of sampled study subjects.

Sequenced *TetA* gene from enteropathogenic tetracycline resistant *E. coli* showed 99% homology with related *TetA* sequences in GenBank. The fact that 55% of tested *E. coli* were resistant to tetracycline and the demonstration of *TetA* genes in some of the isolates would suggest that genes were freely transferable between bacteria *in-vivo* in cases of multi-bacterial infections observed in this study. The homology observed is a frequent finding with tetracycline resistance encoding genes in *E. coli*. *TetA* gene has been reported by Abdi-Hachesoo et al. [17] to be located on bacterial mobile elements and thus horizontally transferable among bacteria strains. The 99 and 100% homology obtained after sequences alignment of the virulence genes confirmed identity and virulence of the pathogenic *E. coli* isolates. This proved that diarrheagenic *E. coli* were indeed isolated from asymptomatic children in the current study. Similar findings have been reported by Quiroga et al. [6], who demonstrated the

presence of EPEC, DAEC, ETEC and EA<sub>g</sub>EC in symptomatic infants. The authors also described 7.5 months of life as the earliest time of *E. coli* colonization.

## ACKNOWLEDGEMENT

This research received funding from Grand Challenges Canada; Grant number S7 0659-01-10 and Swedish Research Council VR reference No.348-2014-3508.

## COMPETING INTERESTS

Authors have declared that no competing interests exist.

## REFERENCES

1. Kaper JB, Nataro JP, Mobley HL. Pathogenic *Escherichia coli*. Nature Reviews Microbiology. 2004;2:123-140.
2. Fratamico PM, DebRoy C, Liu Y, Needleman DS, Baranzoni GM, Feng P. Advances in molecular serotyping and subtyping of *Escherichia coli*, Frontiers in Microbiology. 2016;1-8.
3. Franz E, van Hoek AH, Bouw E, Aarts HJM. Variability of *Escherichia coli* O157 strain survival in manure-amended soil in relation to strain origin, virulence profile, and carbon nutrition profile. Applied and Environmental Microbiology. 2011;77:8088-8098.
4. WHO. Global report on surveillance: Antimicrobial resistance. WHO. 2014;1-7. DOI: 10.1007/s13312-014-0374-3
5. Downie L, Armiento R, Subhi R, Kelly J, Clifford V, Duke T. Community-acquired neonatal and infant sepsis in developing countries: Efficacy of WHO's currently recommended antibiotics – systematic review and meta-analysis. Archives of Disease in Childhood. 2013;98(2):146-154.
6. Quiroga M, Oviedo P, Chinen I, Pegels E, Husulak E, Binztein N, Rivas M, Schiavoni L, Vergara M. Asymptomatic infections by diarrheagenic *Escherichia coli* in children from Misiones, Argentina, during the first twenty months of their lives. Revista do Instituto de Medicina Tropical de São Paulo. 2000;42(1):9-15.
7. Donnenberg MS, Finlay BB. Combating enteropathogenic *Escherichia coli* (EPEC) infections: The way forward. Trends in Microbiology. 2013;21:317-319.
8. Levine MM, Robins-Browne RM. Factors that explain excretion of enteric pathogens by persons without diarrhea. Clinical Infectious Diseases. 2012;55:303-311.
9. Hu J, Torres AG. Enteropathogenic *Escherichia coli*: foe or innocent by stander?. Clinical Infectious Diseases. 2015;21(8):729-734.
10. Feikin DR, Olack B, Bigogo GM, Audi A, Cosmas L, Aura B, Burke H, Njenga MK, Williamson J, Breiman RF. The burden of common infectious disease syndromes at the clinic and household level from population-based surveillance in rural and urban Kenya. PLoS One. 2011;6:0016085.
11. Vidal M, Kruger E, Durán C, Levine M, Prado V, Toro C, Vidal R, Dura C, Lagos R. Single Multiplex PCR Assay to identify simultaneously the six categories of diarrheagenic *Escherichia coli* associated with enteric infections single multiplex PCR assay. Journal of Clinical Medicine. 2005;43(10):5362–5365.
12. Berlutti F, Casalino M, Zagaglia C, Fradiani P, Visca P, Nicoletti M. Expression of the virulence plasmid-carried apyrase gene (*apy*) of enteroinvasive *Escherichia coli* and *Shigella flexneri* is under the control of H-NS and the VirF and VirB regulatory cascade. Infection and Immunity. 1998;66:4957-4964.
13. Stacy-Phipps S, Mecca JJ, Weiss JB. Multiplex PCR assay and simple preparation method for stool specimens detect enterotoxigenic *Escherichia coli* DNA during the course of infection. Journal of Clinical Microbiology. 1995;33:1054-1059.
14. CLSI. Methods for antimicrobial dilution and disk susceptibility testing of infrequently-isolated or fastidious bacteria; approved guideline. CLSI document M45-A Wayne, Pennsylvania, USA Clinical and Laboratory Standards Institute; 2012.
15. Randall LP, Cooles SW, Osborn MK, Piddock LJ, Woodward MJ. Antibiotic resistance genes, integrons and multiple antibiotic resistance in thirty-five serotypes of *Salmonella enterica* isolated from humans and animals in the UK. Journal of Antimicrobial Chemotherapy. 2004; 53:208-216.

16. Van TT, Chin J, Chapman T, Tran LT, Coloe PJ. Safety of raw meat and shellfish in Vietnam: An analysis of *Escherichia coli* isolations for antibiotic resistance and virulence genes. *International Journal of Microbiology*. 2008;124:217-223.
17. Abdi-Hachesoo B, Khoshbakht R, Sharifiyazdi H, Tabatabaei M, Hosseinzadeh S, Asasi K. Tetracycline resistance genes in *Campylobacter jejuni* and *Campylobacter coli* isolated from poultry carcasses. *Journal of Microbiology*. 2014;7(9):e12129.
18. Rono SJ, Rose K, Fabian E, Erick M, Odundo E. Virulence markers in *Escherichia coli* associated with diarrhoea among HIV seropositive and seronegative children below five years in Western Kenya. *European Scientific Journal*. 2014;10(27):1857-7881
19. Bugarel M, Annett M, Patrick F, Lothar B. Virulence gene profiling of enterohemorrhagic (EHEC) and enteropathogenic (EPEC) *Escherichia coli* strains: A basis for molecular risk assessment of typical and atypical EPEC strains. *BMC Microbiology*. 2011;11:142.
20. Sang WK, Boga HI, Waiyaki PG, Schnabel DW, Njeri C, Kariuki SM. Prevalence and genetic characteristics of Shigatoxigenic *Escherichia coli* from patients with diarrhoea in Maasailand, Kenya. *Journal of Infection in Developing Countries*. 2012a;6(2):102.
21. Sang WK, Oundo V, Schnabel D. Prevalence and antibiotic resistance of bacterial pathogens isolated from childhood diarrhoea in four provinces of Kenya. *Journal of Infection in Developing Countries*. 2012b;6(7):572-578.
22. Makobe CK, Sang WK, Kikui G, Kariuki S. Molecular characterization of virulence factors in diarrhoeagenic *Escherichia coli* isolates from children in Nairobi, Kenya. *Journal of Infection in Developing Countries*. 2012;6(8):598-604.
23. Bii CC, Taguchi H, Ouko TT, Muita LW, Wamae N, Kamuja S. Detection of virulence-related genes by multiplex PCR in multidrug-resistant diarrhoeagenic *Escherichia coli* isolates from Kenya and Japan. *Epidemiology and Infection*. 2005;133(4):627-633.
24. Christabel M, Budambula N, Kiiru J, Kariuki S. Characterization of antibiotic resistance in environmental enteric pathogens from Kibera slum in Nairobi-Kenya. *African Journal of Bacteriology Research*. 2012;4:46-54.
25. Kipkorir KC, Philip KB, Partrick OO, David MO, Cyrus A, Paul OA. Epidemiology of antimicrobial resistance among *Escherichia coli* strains in Trans-Nzoia County, Kenya. *Journal of Microbiology and Infectious Diseases*. 2016;6(3):107-112.
26. Oundo JO, Kariuki SM, Boga HI, Muli FW, Iijima Y. High incidence of enteroaggregative *Escherichia coli* among food handlers in three areas of Kenya: A possible transmission route of travelers' diarrhea. *Journal of Travel Medicine*. 2008;15(10):31-8.

#### Biography of author(s)



#### **Dr. N. J. Gitahi**

Department of Public Health Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Nairobi, Kenya.

He obtained his Doctor of Philosophy (Ph.D.) degree in Immunology and is currently working as the Principal Technologist in charge of laboratories in the Department of Public Health Pharmacology and Toxicology, University of Nairobi. He has completed his Master of Science degree in Immunology, Laboratory Sci (Medical), Project Management (Diploma). He has 15 years of professional experience in laboratory consultancy and is supervising 4 M.Sc. students drawn from Kenya and Sweden. His research interests are in the area of bacteriology and molecular immunology. He has worked with research projects in the areas of human waste management & Sanitation, food safety, water quality, antimicrobial resistance, and human wildlife conflict and consulted on various aspects of food safety and domestic water quality. He is the chairman of the Faculty of Veterinary Medicine re-inspection committee for the BVM program. Email-nduhiugitahi@gmail.com



**Dr. P. B. Gathura**

Department of Public Health Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Nairobi, Kenya.

He has completed his Bachelor of Veterinary Medicine degree, Masters degree and Ph.D. degree in Veterinary Public Health from the University of the Nairobi. His areas of specialization include: Zoonoses, immunology, water and environmental Hygiene. Undertaking research in Veterinary Public Health and has several Publications. Has also attended presented papers in various seminars, conferences and workshops. Currently undertaking research on rabies, African Swine Fever and Rift Valley fever. He has also participated in consultancies on behalf of the department and in private capacity. These include establishment of a water laboratory for UNICEF in Rumbek, South Sudan and a slaughterhouse for AMREF TERANUOVA in Turkana, County. He is registered by the National Environment Management Agency (NEMA) as a Lead Expert in Environmental Impact Assessment. And is a member of the Kenya Bureau of Standards Committee on drinking Water Standards. He is also registered by the Kenya Veterinary Association as a Veterinary Surgeon and a member of the Kenya Veterinary Association.



**Professor M. M. Gicheru**

Department of Zoological Sciences, School of Pure and Applied Sciences, Kenyatta University, Nairobi, Kenya.

He completed his Ph.D. degree in Immunology, Master of Science degree in Veterinary public health and Bachelor of veterinary medicine degree. He is working as a professor of immunology and public health. He is also the Dean of School of pure and applied sciences and teaches in the Department of Zoological sciences, Kenyatta University, where he also served as chair of the Department in 2011 to 2015. He is a member of the executive board of Kenya Society for Immunology (KSI), which is affiliated to International Union of Immunological society. His research is on infectious diseases focusing on epidemiology of neglected tropical diseases. His research is biased towards development of vaccines and chemotherapeutic agents for leishmaniasis among other tropic diseases. He has special interest on epidemiology of retroviruses including Human immunodeficiency virus and simian immunodeficiency virus in the context of parasitic infection. He has published widely and supervised several students in both Ph.D. and Master of Science. He is also the chairman of the board of management of St. Cathrine Gatari Girls secondary school, in Murang'a County, Kenya.



**T. W. Githinji**

School of Biological and Physical Sciences, University of Nairobi, Kenya.

She is working as a Senior Technologist in school of Biological and Physical Sciences at the University of Nairobi. She holds a Higher Diploma in Medical Laboratory Sciences and a Bachelor degree of Philosophy in Medical Laboratory Sciences from the Kenya University of Technology. She has worked since 2007 as research assistant on zoonotic infections and later as Laboratory Technologist in Biological Sciences with an interest in forensic and environmental science.



**Dr. A. Nordin**

Department of Energy and Technology, Faculty of Natural Resources and Agricultural Sciences, Swedish University of Agricultural Sciences, Sweden.

She obtained her Ph.D. degree in technology and M.Sc. degree in Biology. She is doing research on the technologies for sanitisation of organic wastes to be used on arable land. She has been working since 2006 with ammonia sanitization collaborating with the Swedish farmers association (LRF), municipalities and sewage treatment companies. Member of steering committee for SPCR 178, certification for source separated sewage fractions. Special interest in slum- and emergency sanitation.

---

© Copyright (2019): Authors. The licensee is the publisher (Book Publisher International).